Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 1/20 | 0.55 |
| ▸ | NAMPT | P43490 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 15/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 12/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 10/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 7/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 7/20 | 0.54 |
| ▸ | HDAC10 | Q969S8 | 7/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 0.54 |
| ▸ | HDAC9 | Q9UKV0 | 7/20 | 0.54 |
| ▸ | HDAC5 | Q9UQL6 | 7/20 | 0.54 |
| ▸ | NCOR2 | Q9Y618 | 7/20 | 0.54 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14376789 | 0.86 | HCAR3 (0.56) | HCAR3NAMPTHDAC6HDAC1HDAC8 | |
| SCHEMBL14376786 | 0.86 | HCAR3 (0.56) | HCAR3NAMPTHDAC6HDAC1HDAC8 | |
| SCHEMBL16904968 | 0.86 | HCAR3 (0.70) | HCAR3NAMPTGRM2 | |
| SCHEMBL14376792 | 0.85 | NAMPT (0.67) | HCAR3NAMPTHDAC6HDAC1HDAC8 | |
| SCHEMBL14376781 | 0.82 | GRM2 (0.61) | HCAR3HDAC6HDAC1HDAC8HDAC3 | |
| SCHEMBL14376797 | 0.80 | NAMPT (0.57) | HCAR3NAMPTGRM2 | |
| SCHEMBL14376779 | 0.78 | HDAC6 (0.70) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL19911614 | 0.77 | GRM2 (0.66) | HCAR3GRM2 | |
| SCHEMBL14376794 | 0.77 | HCAR3 (0.44) | HCAR3NAMPTGRM2 | |
| SCHEMBL29605591 | 0.76 | HDAC6 (0.64) | HCAR3HDAC6HDAC1HDAC8HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150197497-A1 | SELECTIVE INHIBITORS OF HISTONE DEACETYLASE ISOFORM 6 AND METHODS THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-07-16 | — | — | US | disclosed |
| US-20150197497-A1 | SELECTIVE INHIBITORS OF HISTONE DEACETYLASE ISOFORM 6 AND METHODS THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-07-16 | — | — | US | disclosed |
| US-20150197497-A1 | SELECTIVE INHIBITORS OF HISTONE DEACETYLASE ISOFORM 6 AND METHODS THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-07-16 | — | — | US | disclosed |
| WO-2012178208-A2 | SELECTIVE INHIBITORS OF HISTONE DEACETYLASE ISOFORM 6 AND METHODS THEREOF | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY (US) | 2012-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197497-A1 | SELECTIVE INHIBITORS OF HISTONE DEACETYLASE ISOFORM 6 AND METHODS THEREOF | HDAC6, HDAC5, HDAC1 | HCAR3 646/4885NAMPT 325/4885HDAC6 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.